Management of Right Ventricular Failure Due to Pulmonary Embolism

Initial Assessment and Risk Stratification

The European Society of Cardiology recommends immediate anticoagulation with unfractionated heparin and vasopressor support with norepinephrine for hypotensive patients as the cornerstones of RV failure management in PE, with systemic thrombolysis reserved for high-risk PE presenting with cardiogenic shock or persistent hypotension 1, 2, 3
High-risk PE is defined by cardiogenic shock or persistent arterial hypotension, representing acute RV failure with low cardiac output as the leading cause of death, according to the European Heart Journal 2, 3, 4
Intermediate-risk PE includes hemodynamically stable patients with evidence of RV dysfunction on imaging or elevated cardiac biomarkers, as stated by the European Heart Journal 1, 2

The European Heart Journal recommends unfractionated heparin as the preferred agent in high-risk PE with RV failure due to its rapid onset, reversibility, and ability to titrate in unstable patients 1, 3
For non-high-risk PE, low molecular weight heparin or fondaparinux are acceptable alternatives, according to the European Heart Journal 1, 3
Continue parenteral anticoagulation for at least 5-10 days before transitioning to oral agents, as recommended by the European Heart Journal 3, 5

Avoid aggressive fluid resuscitation, as it worsens RV function through mechanical overdistension, according to the European Heart Journal 2, 3, 4
If central venous pressure is low, consider modest fluid challenge of ≤500 mL over 15-30 minutes, as stated by the European Heart Journal 3, 4
Norepinephrine is the vasopressor of choice for hypotensive patients, as it improves RV function through direct positive inotropy while restoring coronary perfusion pressure via peripheral alpha-receptor stimulation, according to the European Heart Journal 1, 3, 4

Administer supplemental oxygen to maintain SpO2 ≥90% (target 94-98%), as recommended by the European Heart Journal 4
Consider high-flow nasal cannula if conventional oxygen therapy is insufficient, according to the European Heart Journal 4
Prefer non-invasive ventilation over intubation when possible, as positive pressure ventilation reduces venous return and worsens RV failure, as stated by the European Heart Journal 4

Systemic thrombolysis is the first-line reperfusion treatment for high-risk PE presenting with cardiogenic shock or persistent arterial hypotension, with very few absolute contraindications, according to the European Heart Journal 1, 6
Surgical pulmonary embolectomy is the recommended alternative when thrombolysis is absolutely contraindicated or has failed to improve hemodynamic status, as stated by the European Heart Journal 1, 6

Inhaled nitric oxide may improve hemodynamics and gas exchange in small studies, providing pulmonary-specific vasodilation, according to the European Heart Journal 2, 3, 5
Levosimendan may restore RV-pulmonary arterial coupling by combining pulmonary vasodilation with increased RV contractility, though data remain preliminary, as stated by the European Heart Journal 2, 3, 5

Continue anticoagulation for at least 3 months, with extended therapy based on individual recurrence versus bleeding risk, as recommended by the European Heart Journal 3, 5
Reassess at 3-6 months for persistent dyspnea or functional limitation to screen for chronic thromboembolic pulmonary hypertension, according to Praxis Medical Insights 7